Introduction
============

Atherosclerosis is a chronic inflammatory vascular disease characterized by infiltration of lipid particles into the arterial wall, leading to inflammatory responses accompanied by endothelial cell dysfunction and recruitment of inflammatory and immune cells ([@b1-ijmm-41-05-2724]). Previous studies have reported that epigenetic mechanisms may be associated with the pathogenesis of atherosclerosis and may account for some of the missing heritability in atherosclerotic cardiovascular disease ([@b2-ijmm-41-05-2724],[@b3-ijmm-41-05-2724]). Epigenetic control of transcription results in a heritable change in gene expression without a change in DNA sequence. DNA methylation and post-translational modifications of histone tails, including lysine methylation and acetylation, are the most common mechanisms that cause changes in DNA accessibility ([@b3-ijmm-41-05-2724]).

DNA methylation is a vital epigenetic modification that has been implicated in the pathogenesis of a number of common complex diseases, including atherosclerosis and cardiovascular disease ([@b4-ijmm-41-05-2724]--[@b12-ijmm-41-05-2724]). DNA methylation serves a role in a variety of cellular processes ([@b5-ijmm-41-05-2724],[@b13-ijmm-41-05-2724]), is affected by environmental factors and is influenced by age, sex and genetic variants ([@b4-ijmm-41-05-2724],[@b6-ijmm-41-05-2724]). As such, elucidating the differences in DNA methylation patterns between atherosclerotic plaque lesions and plaque-free intima tissue may provide an insight into the underlying molecular mechanisms of atherosclerotic cardiovascular disease. Although previous analyses of DNA methylation have identified various CpG sites and genes associated with atherosclerosis in European-ancestry ([@b14-ijmm-41-05-2724]--[@b17-ijmm-41-05-2724]) or Mexican ([@b18-ijmm-41-05-2724]) populations, the pattern of DNA methylation in the atherosclerotic human aorta at the genome-wide level has remained relatively uncharacterized in Japanese individuals.

A previous study examined DNA methylation at \~450,000 CpG sites (Human Methylation 450 BeadChip; Illumina, Inc., San Diego, CA, USA) in 48 human aortic intima specimens obtained from 24 autopsy cases ([@b19-ijmm-41-05-2724]); it was demonstrated that DNA methylation was significantly (P\<1.03×10^−7^) increased at 30 CpG sites and reduced at 15 CpG sites in atheromatous plaque tissues compared with plaque-free intima ([@b19-ijmm-41-05-2724]). In the present study, to further assess the association between DNA methylation and the development of atherosclerosis, a genome-wide analysis of DNA methylation at \~853,000 CpG sites (Infinium MethylationEPIC BeadChip) was performed in 128 human aortic intima specimens obtained from 64 autopsy cases. Compared with the Human Methylation 450 BeadChip array, the newly developed Infinium MethylationEPIC BeadChip array is a more reliable tool for comprehensive DNA methylation analyses ([@b20-ijmm-41-05-2724]). A total of 16 significantly hyper- or hypomethylated novel genes in atheromatous plaque lesions were identified.

Materials and methods
=====================

Study specimens
---------------

Characteristics of the 64 deceased patients from whom tissues were harvested for use in the present study are presented in [Table I](#tI-ijmm-41-05-2724){ref-type="table"}. Inter-individual variation in DNA methylation was detected for the same cell and tissue type of unrelated individuals ([@b21-ijmm-41-05-2724],[@b22-ijmm-41-05-2724]). To avoid the effects of such variation, intra-individual paired comparisons of DNA methylation were performed between atheromatous plaque lesions and corresponding plaque-free intima. A total of 128 postmortem specimens of the aortic intima were obtained from 64 deceased Japanese patients for analysis. The specimens were collected specifically for this study in participating hospitals (Gifu Prefectural Tajimi Hospital, Tajimi; Japanese Red Cross Nagoya First Hospital, Nagoya; Kasugai Municipal Hospital, Kasugai; Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan) between August 2012 and August 2017. A total of 48 of these specimens obtained from 24 subjects were also analyzed in a previous study ([@b19-ijmm-41-05-2724]).

Immunohistochemical analysis of atheromatous plaque lesions and plaque-free intima
----------------------------------------------------------------------------------

Specimens of atheromatous plaque lesions and plaque-free intima were subjected to immunohistochemical analysis as described previously ([@b19-ijmm-41-05-2724]). Formalin (20%)-fixed (6 h at room temperature) and paraffin-embedded sections (3 *µ*m) were deparaffinized, hydrated, immersed in 0.01 mol/l citrate buffer (pH 6.0), and heated for 10 min in a pressure cooker. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 5 min at room temperature and sections were incubated for 30 min at room temperature with mouse monoclonal antibodies against human α-smooth muscle actin (1:100; M0851; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), CD68 (1:100; N1576; Dako; Agilent Technologies, Inc.) and CD45 (1:100; 722071; Nichirei Bioscience, Inc., Tokyo, Japan). Proteinase K (0.1%) pre-treatment (5 min at room temperature) was used for CD68 and CD45. Sections were subsequently incubated for 30 min at room temperature with horseradish peroxidase (HRP)-conjugated goat poly-clonal antibody to rabbit and mouse immunoglobulin (1:100; K5007; Dako; Agilent Technologies, Inc.). Sections were stained with diaminobenzidine for 10 min at room temperature (ChemMate Envision/HRP kit; K5007; Dako; Agilent Technologies, Inc.).

The present study was approved by the Committees on the Ethics of Human Research of: Mie University Graduate School of Medicine, Tsu; Tokyo Metropolitan Institute of Gerontology, Tokyo; Japanese Red Cross Nagoya First Hospital, Nagoya; Gifu Prefectural Tajimi Hospital, Tajimi; and Kasugai Municipal Hospital, Kasugai (all Japan). Written informed consent was obtained from the families of the deceased patients.

Genome-wide analysis of DNA methylation
---------------------------------------

The intima tissue samples were frozen at −80°C immediately following dissection from the aorta. The finely minced (cut to \~1 mm^3^ with a surgical blade) tissue was subsequently mixed with 250 *µ*l phenol-chloroform and centrifuged at 12,000 × g for 5 min at room temperature. The upper aqueous phase was collected for the precipitation of genomic DNA and 100% ethanol containing 0.3 mol/l sodium acetate was added and incubated at −30°C for 30 min. The mixture was then centrifuged at 12,000 × g for 20 min at 4°C and the DNA pellet was dissolved in Tris-EDTA buffer (pH 7.4; Takara Bio, Inc., Otsu, Japan). Bisulfite conversion of genomic DNA was performed using an EZ DNA Methylation kit (Zymo Research Corp., Irvine, CA, USA).

The bisulfite-modified genomic DNA was analyzed for DNA methylation with a DNA methylation-specific microarray (Infinium MethylationEPIC BeadChip, Illumina, Inc.) that included 853,307 CpG sitets distributed throughout the entire genome. A total of 439,562 (91.1%) of these sites were assessed in a previous study ([@b19-ijmm-41-05-2724]) using the Human Methylation 450 BeadChip. Furthermore, 413,745 additional CpG sites, including 333,265 located in enhancer regions, were identified by the Encyclopedia of DNA elements ([@b23-ijmm-41-05-2724]) and FANTOM5 ([@b24-ijmm-41-05-2724]) projects. The Infinium Methylation EPIC BeadChip microarray also interrogates 2,880 CNG (C, cytosine; N, any nucleotide; G, guanine) sites ([@b20-ijmm-41-05-2724]).

Methylation at CpG sites in genomic DNA isolated from atheromatous plaque lesions or plaque-free intima was assessed using a GenomeStudio Methylation Module (Illumina, Inc.). Call rate values for the 128 specimens were all \>99.3%, with a mean value of 99.7%. The DNA methylation level at each CpG site was calculated as the β value, where β = (intensity of the methylated allele)/(intensity of the methylated allele + intensity of the unmethylated allele + 100) ([@b25-ijmm-41-05-2724]).

Statistical analysis
--------------------

The levels of DNA methylation at 853,307 CpG sites (β values) were compared between atheromatous plaque lesions and plaque-free intima using the unpaired Student\'s t-test. To compensate for multiple comparisons, Bonferroni\'s correction for the statistical significance of associations was used. The significance level was thus P\<5.86×10^−8^ (0.05/853,307) for the genome-wide analysis of DNA methylation. Statistical tests were performed using JMP Genomics 6.0 software (SAS Institute, Inc., Cary, NC, USA).

Analysis of public databases
----------------------------

The potential association between CpG sites and genes identified in the present study with atherosclerosis was assessed by searching public databases between January 2007 and October 2017 \[Google Scholar (<http://scholar.google.co.jp>); PubMed (National Center for Biotechnology Information, Bethesda, MD, USA; <https://www.ncbi.nlm.nih.gov/pubmed>), GWAS Catalog (National Human Genome Research Institute, Bethesda, MD, USA and European Bioinformatics Institute, Hinxton, UK; <http://www.ebi.ac.uk/gwas>) and GWAS Central (<http://www.gwascentral.org>)\] for previously associated phenotypes. Genome-wide analyses of DNA methylation or genome-wide association studies for atherosclerosis or cardiovascular disease were included in the results. DNA methylation analyses or association studies of candidate genes were excluded.

Results
=======

Study specimens
---------------

In the present study, the methylation status of 853,307 CpG sites of genomic DNA purified from atheromatous plaque lesions and corresponding plaque-free intima were compared. Manhattan and volcano plots for the genome-wide analysis of differences in methylation status at these sites are presented in [Figs. 1](#f1-ijmm-41-05-2724){ref-type="fig"} and [2](#f2-ijmm-41-05-2724){ref-type="fig"}, respectively. Following Bonferroni\'s correction, the methylation of 2,679 CpG sites was revealed to differ significantly (P\<5.86×10^−8^) between atheromatous plaque lesions and corresponding plaque-free intima. The 50 CpG sites with the lowest P-values (P≤3.48×10^−12^) are presented in [Table II](#tII-ijmm-41-05-2724){ref-type="table"}; to the best of our knowledge, none of these sites have previously been reported to be associated with atherosclerosis.

Genome-wide analysis of gene methylation
----------------------------------------

Of the 2,679 CpG sites significantly associated with atherosclerosis, 2,272 and 407 sites were hyper- or hypomethylated, respectively, in atheromatous plaque lesions compared with plaque-free intima. Among the 2,272 CpG sites that were hypermethylated in atheromatous plaque lesions, 5 had a β value difference (plaque lesion-plaque-free intima) \>0.15 ([Table III](#tIII-ijmm-41-05-2724){ref-type="table"}) and 11 had a β ratio (plaque lesion/plaque-free intima) \>1.50 ([Table IV](#tIV-ijmm-41-05-2724){ref-type="table"}). Among these CpG sites, cg15648389 of homeobox (*HOX) C4* ([@b15-ijmm-41-05-2724]), cg17466857 of *HOXA11*-*HOXA11-AS* ([@b14-ijmm-41-05-2724],[@b15-ijmm-41-05-2724]), cg15700739 of *HOXC4*/*HOXC5* ([@b17-ijmm-41-05-2724]) and cg02384661 of *HOXC11* ([@b15-ijmm-41-05-2724]) have previously been demonstrated to be associated with atherosclerosis.

Among the 407 CpG sites hypomethylated in atheromatous plaque lesions, 15 were observed to have a β value difference \<−0.15 ([Table V](#tV-ijmm-41-05-2724){ref-type="table"}) and 17 sites had a β ratio \<0.67 ([Table VI](#tVI-ijmm-41-05-2724){ref-type="table"}). Of these CpG sites, cg03217995 of *HOXA9* ([@b15-ijmm-41-05-2724]) was previously reported to be associated with atherosclerosis.

Discussion
==========

Atherosclerosis occurs as a result of endothelial damage and dysfunction that leads to the accumulation and oxidation of low-density lipoprotein (LDL) cholesterol in the vessel wall. Monocytes migrate from blood into the subendothelial intima and transform into macrophages, which accumulate lipids as foam cells in the lipid core of the atherosclerotic plaque ([@b26-ijmm-41-05-2724],[@b27-ijmm-41-05-2724]). Inflammatory and thrombotic processes serve primary roles in the formation of atherosclerotic lesions and subsequent plaque rupture that causes acute coronary syndrome ([@b26-ijmm-41-05-2724],[@b27-ijmm-41-05-2724]). A number of mechanisms by which changes in DNA methylation may affect the development of atherosclerosis have been identified. These mechanisms include the promotion of inflammation, endothelial dysfunction, proliferation and migration of smooth muscle cells or monocyte-macrophages, extracellular matrix production, homocysteine metabolism and apoptosis of vascular cells ([@b12-ijmm-41-05-2724],[@b28-ijmm-41-05-2724],[@b29-ijmm-41-05-2724]). However, given the dynamic nature and tissue heterogeneity of atherosclerosis, defining the precise role of DNA methylation in the pathogenesis of this condition is challenging ([@b12-ijmm-41-05-2724]). A marked increase in DNA methylation in atherosclerotic lesions may warrant the development of DNA demethylation agents, including DNA methyltransferase inhibitors, for the treatment of atherosclerotic cardiovascular disease ([@b29-ijmm-41-05-2724]).

Arteriosclerosis is classified into three types: atherosclerosis, Mönckeberg medial sclerosis and arteriolosclerosis ([@b30-ijmm-41-05-2724]). Given that atherosclerosis is the most important pathological change in the development of cardiovascular disease ([@b1-ijmm-41-05-2724],[@b26-ijmm-41-05-2724],[@b27-ijmm-41-05-2724],[@b30-ijmm-41-05-2724]), the aortic intima was examined in the present study. The results revealed that 2,272 and 407 CpG sites were hyper- and hypomethylated, respectively, in genomic DNA isolated from atheromatous plaque lesions compared with matched plaque-free intima. A total of 5 CpG sites had a \>0.15 difference in β values and 11 CpG sites had a β ratio of \>1.50. Among these CpG sites, cg15648389 of *HOXC4* ([@b15-ijmm-41-05-2724]), cg17466857 of *HOXA11*-*HOXA11-AS* ([@b14-ijmm-41-05-2724],[@b15-ijmm-41-05-2724]), cg15700739 of *HOXC4*/*HOXC5* ([@b17-ijmm-41-05-2724]) and cg02384661 of *HOXC11* ([@b15-ijmm-41-05-2724]) have previously been reported to be associated with atherosclerosis. A total of 10 novel CpG sites (cg26809635, cg23786812, cg27178293, cg12873661, cg18040901, cg00576279, cg08857479, cg00862376, cg00187380, cg05951084) that were significantly hypermethylated in atheromatous plaque lesions compared with plaque-free intima were identified in the present study. Of these 10 CpG sites, cg18040901 is located in *the HOX transcript antisense RNA* (*HOTAIR*) gene, whose methylation status has not previously been associated with atherosclerosis. The *HOTAIR* gene is located at chromosome 12q13.13 and encodes a protein that has been reported to promote the proliferation and migration of vascular endothelial cells and to protect these cells against oxidized LDL-induced injury and apoptosis ([@b31-ijmm-41-05-2724]). Endothelial damage and dysfunction are early key processes in the development of atherosclerosis, resulting in the accumulation and oxidation of LDL-cholesterol in the arterial wall ([@b26-ijmm-41-05-2724],[@b27-ijmm-41-05-2724]), and so *HOTAIR* may protect against this ([@b31-ijmm-41-05-2724]).

A total of 15 CpG sites with a \<−0.15 difference in β values and 17 CpG sites with a β ratio of \<0.67 were identified in the present study, including 2 CpG sites (cg13669152, cg13335081) located in enhancer regions as described by the FANTOM5 project ([@b24-ijmm-41-05-2724]). Of these sites, cg03217995 of *HOXA9* ([@b15-ijmm-41-05-2724]) was previously reported to be associated with atherosclerosis. Additionally, 28 novel CpG sites that were significantly hypomethylated in atheromatous plaque lesions compared with plaque-free intima were identified in the present study: cg18461866, cg21007852, cg25227803, cg02886033, cg11052578, cg13669152, cg10224937, cg09699744, cg21310745, cg01016793, cg10374314, cg17820365, cg09164580, cg06136628, cg22055728, cg13335081, cg23345300, cg04122553, cg24719020, cg14554869, cg11348442, cg10893095, cg26437522, cg01428378, cg25541958, cg19783626, cg00980698 and cg12110087. Of these sites, 16 are located in genes whose methylation status has not previously been reported as associated with atherosclerosis, including *fragile histidine triad (FHIT;* cg18461866), *wnt family member 8B (WNT8B*; cg25227803), *HOXA10*-*HOXA10-antisense RNA (AS;* cg10224937 and cg21310745), *HOXC cluster antisense RNA 2* (*HOXC-AS2*; cg09699744), *zinc finger protein 609* (*ZNF609;* cg01016793), *HOXA-AS3* (cg10374314), *growth differentiation factor 6* (*GDF6*; cg17820365, cg09164580), *T-box 20 (TBX20*; cg06136628), *HOXA6* (cg24719020, cg12110087), *tubulin alpha 4a and 4b (TUBA4A*/*TUBA4B*; cg11348442), *coiled-coil domain containing 62* (*CCDC62*; cg01428378), *myomesin 2* (*MYOM2*; cg25541958) and *ribonuclease A family member k6* (*RNASE6*; cg00980698).

*TBX20* is located at chromosome 7p14.2 and encodes a protein that has been demonstrated to protect endothelial cells against oxidized LDL-induced injury via upregulating peroxisome proliferator-activated receptor γ, indicating that it may protect against the development of atherosclerosis ([@b32-ijmm-41-05-2724]). It has also previously been determined that a polymorphism (rs3206736) near *TBX20* is associated with a decrease in diastolic blood pressure ([@b33-ijmm-41-05-2724]). Several of the genes that were demonstrated to be hypomethylated in atherosclerotic tissues in the present study have been reported to be correlated with atherosclerosis-related phenotypes: The *FHIT* gene located at chromosome 3p14.2 is associated with body mass index ([@b34-ijmm-41-05-2724]); the *HOXA10*-*HOXA10-AS* gene at 7p15.2 is expressed differentially in porcine coronary and iliac artery endothelial cells ([@b35-ijmm-41-05-2724]); the *HOXA-AS3* gene at 7p15.2 is associated with chronic venous disease ([@b36-ijmm-41-05-2724]) and monocyte count ([@b37-ijmm-41-05-2724]); *HOXA6* at 7p15.2 is associated with chronic venous disease ([@b36-ijmm-41-05-2724]); and the *TUBA4A*/*TUBA4B* gene at 2q35 is associated with the size distribution of platelets ([@b37-ijmm-41-05-2724]). The remaining novel genes identified in the present study (*WNT8B* located at chromosome 10q24.31; *HOXC-AS2* at 12q13.13; *ZNF609* at 15q22.31; *GDF6* at 8q22.1; *CCDC62* at 12q24.31; *MYOM2* at 8p23.3; and the *RNASE6* gene at 14q11.2) have not previously been reported as associated with atherosclerosis-related phenotypes.

It was previously demonstrated that the methylation at 45 CpG sites differed significantly (P\<1.03×10^−7^) between atheromatous plaque lesions and plaque-free intima ([@b19-ijmm-41-05-2724]). The associations between 23 of these CpG sites \[cg02240539 (P=0.0499), cg04304054 (P=0.0071), cg14521421 (P=0.0033), cg14477581 (P=0.0302), cg00909706 (P=3.49×10^−6^), cg00716848 (P=0.0009), cg08466030 (P=8.08×10^−6^), cg22046201 (P=0.0002), cg18516609 (P=0.0188), cg24634746 (P=8.43×10^−6^), cg26619894 (P=1.20×10^−5^), cg03962451 (P=5.52×10^−5^), cg12556802 (P=4.90×10^−7^), cg10586883 (P=0.0309), cg06208382 (P=1.06×10^−6^), cg18177814 (P=0.0013), cg20556639 (P=1.07×10^−6^), cg09349128 (P=0.0112), cg26724841 (P=0.0379), cg02196592 (P=0.0235), cg16906765 (P=0.0032), cg27647755 (P=1.16×10^−6^), cg01473038 (P=0.0044)\] to atherosclerosis were replicated in the present study.

There are several limitations to the present study: i) The aortic intima specimens comprised heterogeneous cell types, as described previously ([@b19-ijmm-41-05-2724]). ii) Although DNA methylation status may differ among atherosclerosis, Mönckeberg medial sclerosis and arteriolosclerosis, only the aortic intima was examined. iii) The association between atherosclerosis grade and DNA methylation status was not assessed. iv) The effects of hyper- or hypomethylation of CpG sites on the expression of genes were not investigated. v) Given the small sample size of the current study, the statistical power of the genome-wide analysis of DNA methylation was not optimal. vi) The molecular mechanisms underlying the effects of DNA methylation identified in the present study have not been determined definitively. vii) The validation of the results of the present study will require replication with other independent subject panels.

In conclusion, 16 novel genes that were significantly hyper-or hypomethylated in atheromatous plaque lesions compared with plaque-free intima were identified in the present study. These results suggest that the methylation status of these genes may contribute to the pathogenesis of atherosclerosis. The determination of DNA methylation status for the identified CpG sites may prove informative for the assessment of epigenetic risks associated with atherosclerotic cardiovascular disease in the Japanese population.
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![Manhattan plot of P-values in the genome-wide analysis of CpG site methylation differences between atheromatous plaque and plaque-free intima. P-values (y-axis) are plotted as-log~10~(P) with respect to the physical chromosomal positions of the corresponding CpG sites (x-axis). The 10 CpG sites with the lowest P-values are indicated.](IJMM-41-05-2724-g00){#f1-ijmm-41-05-2724}

![Volcano plot for the genome-wide analysis of differences in CpG site methylation between atheromatous plaques and plaque-free intimas. The x- and y-axes represent the difference in β values and P-values as-log~10~(P), respectively. The right and left halves of the plot correspond to hyper- or hypomethylation, respectively, in atheromatous plaque lesions compared with plaque-free intima. The significance threshold is indicated by the horizontal line. The CpG site cg26809635, which was hypermethylated in plaque lesions, had the largest difference in β value (0.1834) and the largest β ratio (3.20) and is indicated on the plot. The CpG sites hypomethylated in plaque lesions with the largest difference in β values (−0.1799, cg18461866) or the smallest β ratio (0.57, cg22055728) are also marked presented.](IJMM-41-05-2724-g01){#f2-ijmm-41-05-2724}

###### 

Patient characteristics (n=64).

  Characteristic                                     Value
  -------------------------------------------------- -----------------------
  Mean age (years) ± SD (range)                      75.8±12.9 (41--95)
  Sex (male/female, %)                               73.4/26.6
  Mean body mass index (kg/m^2^) ± SD (range)        19.8±4.3 (12.2--32.2)
  Current or former smoker (%)                       57.5
  Hypertension (%)                                   40.6
  Diabetes mellitus (%)                              20.3
  Dyslipidemia (%)                                   9.4
  Chronic kidney disease (%)                         32.8
  Myocardial infarction (%)                          21.9
  Ischemic stroke (%)                                9.4
  Cause of death (n)                                 
   Pneumonia                                         13
   Myocardial infarction                             12
   Dissecting aortic aneurysm                        4
   Amyloidosis                                       2
   Dilated cardiomyopathy                            2
   Hypertrophic cardiomyopathy                       2
   Interstitial pneumonia                            2
   Lung cancer                                       2
   Necrotizing enterocolitis                         2
   Amyotrophic lateral sclerosis                     1
   Arrhythmogenic right ventricular cardiomyopathy   1
   Aspergillosis                                     1
   Bacterial meningitis                              1
   Cardiac sarcoidosis                               1
   Chronic obstructive pulmonary disease             1
   Embolic stroke                                    1
   Gastric cancer                                    1
   Heatstroke                                        1
   Huntingdon\'s disease                             1
   Intestinal obstruction                            1
   Ischemic heart disease                            1
   Malignant mesothelioma                            1
   Malnutrition                                      1
   Multiple myeloma                                  1
   Parkinson\'s disease                              1
   Primary biliary cirrhosis                         1
   Pulmonary hypertension                            1
   Relapsing polychondritis                          1
   Renal failure                                     1
   Superior mesenteric artery thrombosis             1
   Traumatic lung contusion                          1
   Valvular heart disease                            1

SD, standard deviation.

###### 

A total of 50 CpG sites with the lowest P-values (P≤3.48×10^−12^) for the comparison of methylation status (β values) between atheromatous plaque lesions and plaque-free intima by a genome-wide analysis of DNA methylation.

  CpG          Chromosome: position   Gene                             Methylation site   Mean β value (plaque)   Mean β value (plaque-free)   β ratio (plaque/plaque-free)   P-value
  ------------ ---------------------- -------------------------------- ------------------ ----------------------- ---------------------------- ------------------------------ --------------
  cg06792393   5:139242953            *NRG2*                           Body               0.7906                  0.6985                       1.13                           1.11×10^−16^
  cg19517104   7:134204895                                                                0.8458                  0.7535                       1.12                           5.60×10^−15^
  cg02580923   12:117470541                                                               0.4173                  0.5093                       0.82                           9.21×10^−15^
  cg15374435   13:80911692            *SPRY2*                          Body               0.7301                  0.5885                       1.24                           1.42×10^−14^
  cg15796536   5:140873082            *PCDHGA8*                        Body               0.8437                  0.7766                       1.09                           1.82×10^−14^
  cg06827792   7:36723794             *AOAH*                           Body               0.8015                  0.7180                       1.12                           1.92×10^−14^
  cg06996940   15:28197405            *OCA2*                           Body               0.8065                  0.7492                       1.08                           3.82×10^−14^
  cg25506501   3:59521337                                                                 0.7693                  0.6500                       1.18                           5.56×10^−14^
  cg22055728   7:27205658             *HOXA9*                          TSS1500            0.1162                  0.2026                       0.57                           7.80×10^−14^
  cg15542608   6:12827379             *PHACTR1*                        Body               0.8312                  0.7371                       1.13                           7.86×10^−14^
  cg07145664   6:2579591                                                                  0.6933                  0.5966                       1.16                           1.21×10^−13^
  cg26968433   12:76397292                                                                0.7965                  0.7363                       1.08                           1.28×10^−13^
  cg24082440   21:33672186            *MRAP*                           Body               0.8245                  0.7598                       1.09                           1.53×10^−13^
  cg27554156   12:13248725            *GSG1*                           Body, TSS200       0.8345                  0.7781                       1.07                           1.64×10^−13^
  cg12433228   2:177486421                                                                0.6642                  0.5898                       1.13                           1.83×10^−13^
  cg12336358   1:114000078            *MAGI3*                          Body               0.7586                  0.6597                       1.15                           2.34×10^−13^
  cg09723384   9:122217063                                                                0.5751                  0.6710                       0.86                           2.89×10^−13^
  cg05454595   5:139243335            *NRG2*                           Body               0.6737                  0.5909                       1.14                           5.69×10^−13^
  cg06019613   2:18717524                                                                 0.4711                  0.6044                       0.78                           7.60×10^−13^
  cg22651416   8:10643634             *PINX1*                          Body               0.8567                  0.7935                       1.08                           8.42×10^−13^
  cg17882587   2:18933408                                                                 0.6727                  0.5779                       1.16                           8.56×10^−13^
  cg19691778   8:97157756             *GDF6*                           Body               0.3900                  0.5395                       0.72                           9.03×10^−13^
  cg17820365   8:97157856             *GDF6*                           Body               0.2811                  0.4348                       0.65                           9.07×10^−13^
  cg15086256   2:222631916                                                                0.7039                  0.6146                       1.15                           9.39×10^−13^
  cg18141318   13:96350690            *DNAJC3*                         Body               0.8180                  0.7723                       1.06                           9.67×10^−13^
  cg01754709   16:84961336                                                                0.7191                  0.6133                       1.17                           9.74×10^−13^
  cg17128320   4:78633646                                                                 0.8804                  0.8235                       1.07                           1.14×10^−12^
  cg16597993   19:16578633            *EPS15L1*                        Body               0.8226                  0.7540                       1.09                           1.20×10^−12^
  cg10224937   7:27208594             *HOXA10-AS*, *HOXA10*, *HOXA9*   Body               0.5089                  0.6669                       0.76                           1.32×10^−12^
  cg12786452   17:62309293            *TEX2*                           5′UTR              0.8392                  0.7737                       1.08                           1.44×10^−12^
  cg05069228   3:61793623             *PTPRG*                          Body               0.7403                  0.6545                       1.13                           1.48×10^−12^
  cg17741799   8:885656                                                                   0.7770                  0.7158                       1.09                           1.49×10^−12^
  cg23854860   7:27208590             *HOXA10-AS*, *HOXA10*, *HOXA9*   Body               0.5480                  0.6949                       0.79                           1.67×10^−12^
  cg03735712   15:35263065            *AQR*                            TSS1500            0.7572                  0.6263                       1.21                           1.69×10^−12^
  cg09164580   8:97157878             *GDF6*                           Body               0.4534                  0.6044                       0.75                           1.73×10^−12^
  cg10166915   14:54260975                                                                0.7714                  0.6711                       1.15                           1.73×10^−12^
  cg17868595   3:90112204                                                                 0.7352                  0.8183                       0.90                           1.74×10^−12^
  cg00246590   12:126968300                                                               0.8422                  0.6984                       1.21                           1.84×10^−12^
  cg19183743   7:27188020             *HOXA6*                          TSS1500            0.3144                  0.4401                       0.71                           1.86×10^−12^
  cg27584713   6:12717016             *PHACTR1*                        TSS1500            0.6815                  0.5733                       1.19                           1.98×10^−12^
  cg02750391   11:14274978            *SPON1*                          Body               0.7800                  0.7205                       1.08                           2.04×10^−12^
  cg21310745   7:27208454             *HOXA10-AS*, *HOXA10*, *HOXA9*   TSS200, body       0.6244                  0.7815                       0.80                           2.22×10^−12^
  cg16739092   20:17519424            *BFSP1*                          Body, 5′UTR        0.3781                  0.4932                       0.77                           2.23×10^−12^
  cg03804397   11:76925617            *MYO7A*                          Body               0.7302                  0.6427                       1.14                           2.31×10^−12^
  cg22790931   7:39017455             *POU6F2*                         TSS200             0.9070                  0.8683                       1.04                           2.36×10^−12^
  cg23080761   12:111857575           *SH2B3*                          Body               0.8194                  0.7611                       1.08                           3.04×10^−12^
  cg13913011   9:132711808            *FNBP1*                          Body               0.7628                  0.6517                       1.17                           3.18×10^−12^
  cg08272913   18:68079266                                                                0.6156                  0.4664                       1.32                           3.33×10^−12^
  cg20337028   17:75181836            *SEC14L1*                        Body, 5′UTR        0.7624                  0.6871                       1.11                           3.44×10^−12^
  cg12873661   1:166277235                                                                0.6713                  0.5187                       1.29                           3.48×10^−12^

TSS1500 (200), within 1,500 (200) bp from the transcription start site; P\<5.86×10^−8^ was considered statistically significant. NRG2, neureg-ulin 2; SPRY2, sprout RTK signaling antagonist 2; PCDHGA8, protocadherin gamma subfamily A8; AOAH, acyloxyacyl hydrolase; OCA2, oculocutaneous albinism type 2; HOXA9, homeobox A9; PHACTR1, phosphatase actin regulator 1; MRAP, melanocortin 2 receptor accessory protein; GSG1, germ cell associated 1; MAGI3, membrane associated guanylate kinase, WW and PD2 domains-containing 3; PINX1, PIN2/TERF1 interacting telomerase inhibitor 1; GDF6, growth differentiation factor 6; DNAJC3, DnaJ heat shock protein family member C3; EPS1SL1, epidermal growth factor receptor pathway substrate 13-like; AS, antisense RNA; TEX2, testis expressed 2; PTPRG, protein tyrosine phosphatase receptor type G; AQR, Aquarius intron-binding splceosomal factor; SPON1, spondin 1; BFSP1, beaded filament structural protein 1; MYO7A, myosin VIIa; SH2B3, SH2B adaptor protein 3; FNBP1, formin binding protein 1; SEC14L1, SEC14-like lipid binding 1; TSS, transcription start site; UTR, untranslated region.

###### 

Five CpG sites whose methylation status differed significantly (P\<5.86×10^−8^) between atheromatous plaque lesions and plaque-free intima with a difference in β values (plaque lesion-plaque-free intima) of \>0.15.

  CpG          Chromosome: position   Gene      Mean β value (plaque)   Mean β value (plaque-free)   β ratio (plaque/plaque-free)   Difference in β values (plaque-plaque-free)   P-value
  ------------ ---------------------- --------- ----------------------- ---------------------------- ------------------------------ --------------------------------------------- --------------
  cg26809635   12:54355087                      0.2669                  0.0835                       3.1957                         0.1834                                        6.35×10^−10^
  cg23786812   7:156296516                      0.5526                  0.3922                       1.4090                         0.1604                                        4.12×10^−12^
  cg15648389   12:54448769            *HOXC4*   0.5564                  0.4005                       1.3893                         0.1559                                        3.60×10^−11^
  cg27178293   12:54371246                      0.4042                  0.2484                       1.6270                         0.1558                                        1.24×10^−8^
  cg12873661   1:166277235                      0.6713                  0.5187                       1.2941                         0.1526                                        3.48×10^−12^

HOXC4, homeobox C4.

###### 

Eleven CpG sites whose methylation status differed significantly (P\<5.86×10^−8^) between atheromatous plaque lesions and plaque-free intima with a β ratio (plaque/plaque-free) of \>1.50.

  CpG          Chromosome: position   Gene                    Methylation site   Mean β value (plaque)   Mean β value (plaque-free)   β ratio (plaque/plaque-free)   P-value
  ------------ ---------------------- ----------------------- ------------------ ----------------------- ---------------------------- ------------------------------ --------------
  cg26809635   12:54355087                                                       0.2669                  0.0835                       3.20                           6.35×10^−10^
  cg18040901   12:54357530            *HOTAIR*                Body               0.1839                  0.0979                       1.88                           6.12×10^−11^
  cg00576279   12:54427293            *HOXC4*, *HOXC5*        5′UTR, body        0.2516                  0.1419                       1.77                           5.04×10^−9^
  cg17466857   7:27225528             *HOXA11-AS*, *HOXA11*   Body, TSS1500      0.2618                  0.1479                       1.77                           1.16×10^−8^
  cg08857479   12:54369987            *HOXC11*                3′UTR              0.3479                  0.2112                       1.65                           1.93×10^−8^
  cg27178293   12:54371246                                                       0.4042                  0.2484                       1.63                           1.24×10^−8^
  cg15700739   12:54427700            *HOXC4*, *HOXC5*        5′UTR, body        0.3313                  0.2050                       1.62                           1.15×10^−9^
  cg00862376   12:54343711                                                       0.2745                  0.1708                       1.61                           5.27×10^−9^
  cg00187380   12:54427384            *HOXC4*, *HOXC5*        5′UTR, body        0.3373                  0.2144                       1.57                           2.21×10^−8^
  cg02384661   12:54369638            *HOXC11*                3′UTR              0.3804                  0.2450                       1.55                           5.36×10^−9^
  cg05951084   12:54343681                                                       0.3480                  0.2304                       1.51                           7.64×10^−9^

TSS1500, within 1,500 bp from the transcription start site. HOTAIR, HOX transcript antisense RNA; HOX, homeobox; -AS, antisense RNA; UTR, untranslated region; TSS, transcription start site.

###### 

Fifteen CpG sites whose methylation status differed significantly (P\<5.86×10^−8^) between atheromatous plaque lesions and plaque-free intima with a difference in β values (plaque lesion-plaque-free intima) of \<−0.15.

  CpG          Chromosome: position   Gene                             Mean β value (plaque)   Mean β value (plaque-free)   β ratio (plaque/plaque-free)   Difference in β values (plaque-plaque-free)   P-value
  ------------ ---------------------- -------------------------------- ----------------------- ---------------------------- ------------------------------ --------------------------------------------- --------------
  cg18461866   3:59996864             *FHIT*                           0.3759                  0.5558                       0.6763                         −0.1799                                       1.78×10^−10^
  cg21007852   7:27203546             *HOXA9*                          0.5134                  0.6904                       0.7435                         −0.1771                                       2.96×10^−11^
  cg25227803   10:102239027           *WNT8B*                          0.3980                  0.5727                       0.6951                         −0.1746                                       1.84×10^−11^
  cg03217995   7:27203430             *HOXA9*                          0.5377                  0.7107                       0.7565                         −0.1731                                       5.49×10^−10^
  cg02886033   7:27208114                                              0.5367                  0.7048                       0.7615                         −0.1681                                       7.82×10^−10^
  cg11052578   21:39695801                                             0.3391                  0.5064                       0.6697                         −0.1672                                       4.05×10^−8^
  cg13669152   6:130923610                                             0.4987                  0.6580                       0.7579                         −0.1593                                       2.46×10^−8^
  cg10224937   7:27208594             *HOXA10-AS*, *HOXA10*, *HOXA9*   0.5089                  0.6669                       0.7631                         −0.1580                                       1.32×10^−12^
  cg09699744   12:54390705            *HOXC-AS2*                       0.3719                  0.5298                       0.7020                         −0.1579                                       1.60×10^−10^
  cg21310745   7:27208454             *HOXA10-AS*, *HOXA10*, *HOXA9*   0.6244                  0.7815                       0.7990                         −0.1571                                       2.22×10^−12^
  cg01016793   15:64894722            *ZNF609*                         0.4212                  0.5773                       0.7297                         −0.1561                                       1.03×10^−11^
  cg10374314   7:27189610             *HOXA-AS3*                       0.5017                  0.6558                       0.7650                         −0.1541                                       4.03×10^−11^
  cg17820365   8:97157856             *GDF6*                           0.2811                  0.4348                       0.6465                         −0.1537                                       9.07×10^−13^
  cg09164580   8:97157878             *GDF6*                           0.4534                  0.6044                       0.7502                         −0.1510                                       1.73×10^−12^
  cg06136628   7:35289993             *TBX20*                          0.2790                  0.4293                       0.6498                         −0.1503                                       4.81×10^−10^

FHIT, fragile histidine triad; HOX, homeobox; WNT8B, wnt family member 8B; -AS, antisense RNA; ZNF609, zinc finger protein 609; GDF6, growth differentiation factor 6; TBX20, T-box 20.

###### 

Seventeen CpG sites whose methylation status differed significantly (P\<5.86×10^−8^) between atheromatous plaque lesions and plaque-free intima with a β ratio (plaque/plaque-free) of \<0.67.

  CpG          Chromosome: position   Gene                 Methylation site   Mean β value (plaque)   Mean β value (plaque-free)   β ratio (plaque/plaque-free)   P-value
  ------------ ---------------------- -------------------- ------------------ ----------------------- ---------------------------- ------------------------------ --------------
  cg22055728   7:27205658             *HOXA9*              TSS1500            0.1162                  0.2026                       0.57                           7.80×10^−14^
  cg13335081   8:66894111                                                     0.1758                  0.2913                       0.60                           1.67×10^−8^
  cg23345300   2:177000621                                                    0.1669                  0.2752                       0.61                           3.81×10^−8^
  cg04122553   14:21250646                                                    0.1587                  0.2615                       0.61                           3.43×10^−9^
  cg24719020   7:27187943             *HOXA6*              TSS1500            0.2018                  0.3324                       0.61                           1.51×10^−9^
  cg14554869   5:74231171                                                     0.1656                  0.2630                       0.63                           9.29×10^−11^
  cg11348442   2:220117784            *TUBA4B*, *TUBA4A*   TSS200, body       0.1177                  0.1869                       0.63                           5.22×10^−8^
  cg10893095   6:85478296                                                     0.2545                  0.4008                       0.64                           1.10×10^−10^
  cg26437522   7:27174169                                                     0.2220                  0.3460                       0.64                           4.59×10^−9^
  cg01428378   12:123259789           *CCDC62*             Body               0.1784                  0.2770                       0.64                           2.67×10^−8^
  cg17820365   8:97157856             *GDF6*               Body               0.2811                  0.4348                       0.65                           9.07×10^−13^
  cg25541958   8:1992965              *MYOM2*              TSS200             0.1679                  0.2585                       0.65                           4.63×10^−11^
  cg06136628   7:35289993             *TBX20*              Body               0.2790                  0.4293                       0.65                           4.81×10^−10^
  cg19783626   7:98311436                                                     0.2204                  0.3366                       0.65                           3.72×10^−12^
  cg00980698   14:21250509            *RNASE6*             3′UTR              0.1554                  0.2365                       0.66                           1.67×10^−10^
  cg12110087   7:27187691             *HOXA6*              TSS1500            0.2103                  0.3168                       0.66                           8.08×10^−9^
  cg11052578   21:39695801                                                    0.3391                  0.5064                       0.66                           4.05×10^−8^

TSS1500 (200), within 1,500 (200) bp from the transcription start site. HOX, homeobox; TUBA4B/4A, tubulin alpha 4a and 4b; CCDC62, coiled-coil domain containing 62; GDF6, growth differentiation factor 6; MYOM2, myomesin 2; TBX2-, T-box 20; RNASE6, ribonuclease A family member k6; TSS, transcription start site; UTR, untranslated region.
